Milestone reached in pre-clinical development!
Theralase Technologies Inc. announced today that it has identified its lead Photo Dynamic Compound (PDC) that it plans to enter into a Health Canada Clinical Trial Application (CTA)/Food and Drug Administration (FDA) Investigational New Drug (IND) Application for the destruction of Non Muscle Invasive Bladder Cancer (NMIBC) in 2015.
For more on the story, Click Here